ArticlePloS one2025
Exploring the mechanism of Synechococcus sp. XM-24 in gastric cancer treatment via network pharmacology and molecular docking.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe investigated the potential molecular mechanisms of Synechococcus sp. XM-24 affect gastric cancer (GC) development. Furthermore, this study aimed to provide a theoretical basis for developing novel therapeutic drugs for treating GC.
methodsThe interactions between Synechococcus sp. XM-24 and targeted proteins in GC were analyzed through network pharmacology and molecular docking. Molecular dynamics (MD) simulation of the protein-small molecule complex obtained from molecular docking were performed using the Gromacs v2022.03 software. Based on the intersecting target genes of Synechococcus sp. XM-24 and GC, Gene Ontology function and Kyoto Encyclopedia of Genes and Genomes analyses were performed to obtain the associated biological processes (BP), cellular components (CC), molecular functions (MF), and signal transduction pathways.
resultsIn total, 609 intersecting targets were identified between Synechococcus sp. XM-24 and GC, with nine key target genes (AKT1, ALB, IL1B, SRC, STAT3, EGFR, HSP90AA1, ESR1, and BCL2) being identified as active components of Synechococcus sp. XM-24. These key target genes were involved in 1,028 BP, 110 CC, 312 MF, and 200 signaling pathways. The enriched signaling pathways mainly included the cancer pathway, metabolic pathway, phosphatidylinositol 3-kinase-protein kinase B(PI3K-AKT) signaling pathway, and Rat sarcoma signaling pathway. Additionally, molecular docking analysis revealed strong binding activities between 10 active components of Synechococcus sp. XM-24, including methyl vaccenate, allyl methallyl ether, and 11-octadecenoic acid, with key target proteins such as albumin (ALB). MD simulations demonstrated a stable binding of ALB and methyl vaccenate, with a binding free energy of -48.39 kcal/mol.
conclusionsOverall, the findings of this study reveal the therapeutic potential of Synechococcus sp. XM-24 in the prevention and treatment of GC, along with providing a theoretical basis for further development in GC treatment employing Synechococcus sp. XM-24.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.